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Background: Prognosis and treatment of patients with breast carcinoma of no special type (NST) is dependent on
a few established parameters, such as tumor size, histological grade, lymph node stage, expression of estrogen
receptor, progesterone receptor, and HER-2/neu, and proliferation index. The original Nottingham Prognostic Index
(NPI) employs a three-tiered classification system that stratifies patients with breast cancer into good, moderate, and
poor prognostic groups. The aim of our study was to use robust immunohistochemical methodology for determination
of ER, PR, HER-2/neu, Ki-67, p53, and Bcl-2, and to observe differences in the expression of these markers when patients
are stratified according to the original, three-tiered Nottingham Prognostic Index.
Methods: Paraffin blocks from 120 patients diagnosed with breast carcinoma, NST, were retrieved from our archive.
Cases included in the study were female patients previously treated with modified radical mastectomy and axillary
dissection.
Results: Our study demonstrates that expression of markers of good prognosis, such as ER, PR, and Bcl-2, is seen with
higher frequency in good and moderate NPI groups. In contrast, overexpression of HER-2/neu, a marker of adverse
prognosis, is more frequent in moderate and poor NPI groups. High proliferation index, as measured by Ki-67, is seen
in moderate and poor NPI groups, whereas low proliferation index is seen in good NPI groups.
Conclusions: These data confirm that the original, three-tiered NPI statistically correlates with the expression of prognostic
immunohistochemical markers in breast carcinoma NST.
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The prognosis and treatment of patients with breast
carcinoma of no special type (NST) are dependent on a
few established parameters, such as tumor size, histological
grade, lymph node stage, expression of estrogen receptor
(ER), progesterone receptor (PR), overexpression of
human epidermal growth factor receptor 2 HER-2), and
proliferation index determined by Ki-67 [1-5].* Correspondence: fkurshumliu@gmail.com
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article, unless otherwise stated.Incorporation of genetic information, as determined
by gene expression profiling (GEP) [6-8], is becoming a
standard of care for patients with breast cancer [9-14].
However, this methodology is mainly restricted to
selected institutions and issubject to issues related to
sample processing, data interpretation, reproducibility,
validation, feasibility, and cost [2]. These are of critical
relevance in considering the need to identify the molecular
features of individual tumors in routine practice [2].
The Nottingham Prognostic Index Plus (NPI+)
evaluates the expression of ten protein biomarkers by
immunohistochemistry in order to stratify patients
into seven core classes: class 1 (Luminal A), class 2
(Luminal N), class 3 (Luminal B), class 4 (Basal, p53tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 2 Antibodies, vendor, pretreatment, and dilution
Antibody Clone Source Pretreatment Dilution
ER 1D5 DAKO pH 9.0 1:35
PR 636 DAKO pH 9.0 1:50
HER-2 HercepTest DAKO pH 6.1 Ready to use
Ki-67 MIB-1 DAKO pH 9.0 1:100
p53 DO-7 DAKO pH 9.0 1:1000
Bcl-2 124 DAKO pH 9.0 1:100
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positive, ER positive), and class 7 (HER-2/neu positive, ER
negative) [1,2]. These classes are comparable to those
identified by GEP [1,2].
The origins of this system date from a study in 1992,
according to which the Nottingham Prognostic Index
(NPI) is a numerical value that is calculated by adding
the values of tumor diameter (multiplied by a coefficient
of 0.2), histological grade (1 to 3), and lymph node stage
(1 to 3) [15]. The original NPI employed a three-tiered
classification system distinguishing good, moderate, and
poor prognostic groups with cut-off points between
the values ≤3.4, 3.4 to 5.4, and >5.4 [15]. Over the years,
this system has been modified to a four-to-six-tiered
stratification with slight variability in interpretation
[2,16,17].
The aim of our study was to use robust immunohisto-
chemical methodology for determination of ER, PRHER-2/
neu, Ki-67, p53, and Bcl-2, and to observe differences in
expression of these markers when patients are stratified
according to the original, three-tiered, N PI.
Methods
Paraffin blocks from 120 female patients diagnosed with
breast carcinoma, NST, were retrieved from our archive.
Patients had been treated with modified radical mastectomy
and axillary dissection, and staged according to the
pathologic tumor-node-metastasis (pTNM) system.
Histological grade was determined through the Nottingham
grading system, and the NPI was calculated accordingly
(Table 1). Cases subjected to neoadjuvant therapy
and with multifocal and/or multicentric foci were
excluded from the study. Biopsy samples had been
fixed in 10% neutral buffered formalin and sectioned in
3- 4micron sections. All biopsy samples were previously
evaluated by two independent pathologists. The study
is conducted in compliance with the principles of
Declaration of Helsinki and approved by the Ethical
and Professional Committee.
Immunohistochemistry
Antigens were retrieved by placing the slides in target
retrieval solution for 45 min at 95 98°C (Table 2).
The slides were incubated with the primary antibody






*NPI = tumor size in cm x 0.2 + histological grade [1- 3] + number of positive
lymph nodes [1 = 0 nodes; 2 = 1 3 nodes; 3 > 3 nodes].polymer conjugated with peroxidase and secondary
antibody (EnVision+, DAKO, Denmark, K534011) for
30 min.
Interpretation of results
The interpretation of ER, PR, and HER-2/neu immuno-
histochemistry was carried out according to American
Society of Clinical Oncology (ASCO) guidelines [18,19].
A positive result for ER and PR was any nuclear stain
observed in more than 1% of the tumor cells [18].
Non-neoplastic epithelium of the normal terminal
duct-lobular unit was used as an internal control. The
staining pattern for HER-2/neu was scored on a scale
of 0 to 3+. Negative for HER-2/neu overexpression
were scores 0 and 1+. Positive results were membranous
staining with a score of 3+ [19]. Cases with “equivocal”
results (2+) were excluded in order to restrict to immuno-
histochemical methodology.
The interpretation of proliferative index as measured
by Ki-67 was carried out by estimating the percentage of
cells with nuclear stain in the most mitotically active
areas. The cut-off point between low and high proliferative
index was 14%, according to St. Gallen criteria [20].
Cytoplasmic staining with Bcl-2 was interpreted by
using a cut-off value of 10% between negative and positive
results [21].
The interpretation of p53 was carried out by estimating
the proportion of tumor cells with nuclear stain. A
positive result was any value above 10% [22].
The data were statistically analyzed with the chi-square
and Kruskal-Wallis methods.
Results
Paraffin blocks from 120 female patients diagnosed
with breast carcinoma, NST, were analyzed. Positive
expression of ER and PR was inversely related to the
NPI numerical value. This difference was statistically
significant between the NPI groups P < 0.01); see Figure 1
and Table 3.
Overexpression of HER-2/neu was in direct correlation
with NPI numerical value. This difference was statistically
significant between the NPI groups (P = 0.01); see Figure 1
and Table 3. Similarly, high proliferation index, as
measured by Ki-67, was more frequent with increasing
Figure 1 Expression of ER, PR, HER-2/neu, Ki-67, Bcl-2, and p53 in NPI groups.
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http://www.wjso.com/content/12/1/243NPI value, being statistically significant between the
groups (P < 0.01, Figure 1 and Table 3). In contrast, low
proliferation index, as measured by Ki-67, was in inverse
correlation with NPI value (P < 0.01).
As with ER, expression of Bcl-2 was inversely related
to NPI numerical value. This difference was statistically
significant (P < 0.01), reemphasizing its role as a marker
of good prognosis. Expression of antioncogenic proteinTable 3 Immunohistochemical marker expression in respectiv
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52.50% 47.50% 47.50%p53 was heterogeneously distributed in the NPI groups
without any statistically significant difference (P = 0.057
Figure 1 and Table 3).
Discussion
There is ample evidence from clinical, morphological,
and molecular genetic studies that breast cancer is a
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http://www.wjso.com/content/12/1/243The continuous endeavors of breast cancer researchers
are the determination of clinical, morphological, molecular,
and genetic indicators for accurate prognostic stratification
of patients and the determination of individually tailored
therapy [1-16].
Many studies have evaluated combinations of different
parameters in order to develop a prognostic profile or
prognostic index [1-4,6-12,14,15].
It is generally known that prognosis and treatment of
patients with breast carcinoma, NST, are dependent on a
few established parameters, such as tumor size, histological
grade, lymph node stage, expression of estrogen receptor
(ER), progesterone receptor (PR), overexpression of
human epidermal growth factor receptor 2 HER-2),
and proliferation index determined by Ki-67 [1-16].
Current data also support the use of molecular studies
for determination of gene expression profile (GEP), but
in some situations, integration of clinico-pathological
variables with molecular tests, reproducibility, and cost
limit their use [1,2].
The Nottingham Prognostic Index Plus (NPI+) evaluates
expression of ten protein biomarkers by immunohisto-
chemistry in order to stratify the patients into seven core
classes: class 1 (luminal A), class 2 (luminal N), class 3
(luminal B), class 4 (basal, p53 altered), class 5 (basal,
p53 normal), class 6 (HER-2/neu positive, ER positive), and
class 7 (HER-2/neu positive, ER negative) [1,2]. These
classes are comparable to those identified by GEP [1,2].
The origins of this system date from the study of 1992
[15]. The original NPI employed a three-tiered stratification
system distinguishing good, moderate, and poor prognostic
groups [15]. This system has been validated through long
periods of clinical follow-up and large multinational and
multiinstitutional studies [8-14].
Immunohistochemical determination of ER, PR,
HER-2/neu, and Ki-67 is part of the basic histopathological
procedures of breast cancer diagnosis in most institutions.
Expression of hormone receptors generally entails
favorable prognosis and is an indication for hormonal
therapy. In contrast, HER-2/neu overexpression is a
marker of adverse prognosis and an indication for
trastuzumab therapy.
In line with this general knowledge, we observed
that expression of ER and PR was more frequent in
NPI groups with favorable prognosis. This expression
declined significantly with increasing numerical value.
HER-2/neu overexpression was in direct correlation with
NPI value. As with ER and PR expression, the frequency
of HER-2/neu overexpression was statistically different
between the three NPI groups.
Proliferation index, as measured by Ki-67, is a proven
prognostic marker [20]. In our study, low and highKi-67
indices were in statistical correlation with low and
highNPI numerical value. Some studies have reportedon the value of Bcl-2 expression as a good prognostic
indicator in breast carcinoma [21,23]. The gene of this
protein is activated subsequently to the activation of the
estrogen receptor gene, and thus is an indication of
ER presence [23]. In our study we observed a strong
correlation between ER and Bcl-2 expression, and
hence an inverse statistical correlation between Bcl-2
and NPI value.
This is also supported in the study by Zhang et al.
[24], who concluded the following: 1) expression of
Bcl-2 is associated with better response to hormonal
therapy, and 2) expression of Bcl-2 is a good prognostic
marker irrespective of the nodal status.
Some early studies have reported an inverse correl-
ation between expression of Bcl-2 and immunohisto-
chemical detection of EGFR, HER-2/neu, and p53 [25,26].
Alsabeh et al. [27] observed that Bcl-2 expression is more
common in breast carcinomas with low MIB count.
In our study, expression of antioncogenic protein p53
was heterogeneously distributed in NPI groups without
any statistical correlation. Also, expression of this
protein was not in correlation with expression of other
markers.
There is sufficient evidence to support the role of
p53 in breast carcinogenesis despite observations that
mutations of this gene are found at lower frequency
compared to those in other solid tumors [28]. Studies
related to p53 protein regulation have described new
transcription products of p53, highlighting alternative
molecular mechanisms, besides mutations, through which
p53 is deactivated in breast cancer [28]. The molecular
analysis of different stages of p53 protein activity may have
diagnostic, prognostic, and therapeutic implications in the
future [28].
In early stages of the study, we used a four-to-sixtiered
NPI stratification. Even though frequency of expression
of prognostic markers was in correlation with NPI value,
the statistical significance between the groups could
not be reached with respective cut-off values. Hence,
the original, three-tiered NPI stratification with cut-off
points between values ≤3.4, 3.4 5.4, and >5.4 [15] was
more appropriate in statistical terms.
Conclusion
In conclusion, our study demonstrates that expression of
ER, PR, and Bcl-2 is seen with higher frequency in good
and moderate NPI groups. In contrast, overexpression
of HER-2/neu is more frequent in moderate and poor
NPI groups. The Ki-67 proliferation index is in direct
correlation with NPI value.
These data confirm that the original, three-tiered
Nottingham Prognostic Index statistically correlates
with expression of prognostic immunohistochemical
markers in breast carcinoma, NST.
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